Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review
3
Citation
38
Reference
10
Related Paper
Citation Trend
Abstract:
Lurbinectedin was approved on June 15, 2020 by the Food and Drug Administration with the brand name ZEPZELCA as the first systematic approved therapy for patients having Small Cell Lung Cancer (SCLC).In this review, an attempt is made to summarize different aspects of Lurbinectedin, including the pathophysiology, chemistry, chemical synthesis, mechanism of action, adverse reactions, and pharmacokinetics. Special attention is given to various reported clinical trials of lurbinectedin.A comprehensive literature search was conducted in the relevant databases like ScienceDirect, PubMed, ResearchGate and Google Scholar to identify studies. After a thorough study of these reports, significant findings/data were collected and compiled under suitable headings. Important findings related to clinical trials have been tabulated.Lurbinectedin is known to act by inhibiting the active transcription of encoding genes, thereby suppressing tumor-related macrophages with an impact on tumour atmosphere. Lurbinectedin has emerged as a potential drug candidate for the treatment of Small-Cell Lung Cancer (SCLC).Lung cancer is still a leading cause of cancer mortality in the world. The incidence of lung cancer in developed countries started to decrease mainly due to global anti-smoking campaigns. However, the incidence of lung cancer in women has been increasing in recent decades for various reasons. Furthermore, since the screening of lung cancer is not as yet very effective, clinically applicable molecular markers for early diagnosis are much required. Lung cancer in women appears to have differences compared with that in men, in terms of histologic types and susceptibility to environmental risk factors. This suggests that female lung cancer can be derived by carcinogenic mechanisms different from those involved in male lung cancer. Among female lung cancer patients, many are non-smokers, which could be studied to identify alternative carcinogenic mechanisms independent from smoking-related ones. In this paper, we reviewed molecular susceptibility markers and genetic changes in lung cancer tissues observed in female lung cancer patients, which have been validated by various studies and will be helpful to understand the tumorigenesis of lung cancer.
Genetic predisposition
Epidemiology of cancer
Cite
Citations (9)
Drug Administration
Drug approval
Dietary supplement
Drug labeling
Cite
Citations (2)
Advisory committee
Vena cava
Cite
Citations (1)
This study uses data from US Food and Drug Administration (FDA) databases to quantify approval of high-risk cardiovascular devices for use in pediatric populations and assess the clinical evidence supporting the approvals.
Drug approval
Drug labeling
Drug Administration
Cite
Citations (5)
The Food and Drug Administration (FDA) is reclassifying the penile rigidity implant from class III to class II when intended to provide penile rigidity in men diagnosed as having erectile dysfunction. The special control is the FDA guidance document entitled "Guidance for the Content of Premarket Notifications for Penile Rigidity Implants." This action is taken on FDA's own initiative based on new information. This action is being taken under the Federal Food, Drug, and Cosmetic Act (the act), as amended by the Medical Device Amendments of 1976, the Safe Medical Devices Act of 1990, and the FDA Modernization Act of 1997.
Medical device
Cite
Citations (0)
Abstract The Food and Drug Administration (FDA) is a regulatory agency of the United States federal government. This article describes the scope of work of each of the FDA's major components, and addresses the role of statisticians at FDA.
Scope (computer science)
Drug approval
Cite
Citations (0)
Drug Administration
Cite
Citations (4)
In September, the Food and Drug Administration (FDA) clinical trials workshop proposed the development of symptom-reduction trials. Participants in these trials must have a certain, carefully chosen indicator symptom, a symptom or condition believed to be caused by immune deficiency or otherwise by HIV infection, and which is unlikely to resolve on its own. The subjects are treated with antiviral agents, immunomodulators, or other drugs to see if the symptom goes away. This type of study differs in that the conventional trial measures disease progression by waiting for new symptoms or conditions to appear, which usually takes a great deal of time. It is hoped that this type of trial will validate various markers of improvement over months, rather than years.
Drug trial
Clinical Research
Drug Administration
Drug Development
Cite
Citations (0)
Limited studies have examined the association between lung cancer and bronchiectasis (BE). This study evaluated the regional association between BE and lung cancer by analyzing the lobar location of lung cancer in patients with underlying BE. This clustered multi-level study enrolled patients who had underlying BE and were newly diagnosed with lung cancer between January 1, 2010 and May 30, 2013 in two referral hospitals in South Korea. By analyzing the presence of lung cancer and underlying BE as event variables at the level of lung lobes on chest computed tomography (CT), we evaluated the association of BE and lung cancer by the locations of the diseases. Eighty-one patients with BE and combined lung cancer were enrolled. Within 486 lung lobes of the patients, combined BE and lung cancer in the same lobe was found in 11 lobes (2.3 %). Using the general estimating equation assuming BE as a risk factor of lung cancer, the results indicated that the prevalence of lung cancer was significantly lower in the lobes with pre-existing BE (β = −1.09, p-value = 0.001). Regionally, pre-existing BE was associated with a lower risk of the occurrence of lung cancer in the same lobe.
Cite
Citations (7)
In the world, there are many tests that allow the detection of HPV infection. These tests are based on different operating principles and have different levels of sensitivity. The first test to detect HPV infection was approved by the Food and Drug Administration in 2003. Since then, the FDA has approved five more commercial tests for this purpose, the last one in 2018. This paper discusses the principles of molecular tests to detect HPV, which have been approved by the FDA, the main differences between them, as well as their advantages and disadvantages.
Hybrid capture
Drug Administration
Cite
Citations (6)